HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Estrogens (Estrogen)

Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.

Also Known As:

Estrogen; Estrogenic Agents; Estrogenic Compounds; Agents, Estrogenic; Compounds, Estrogenic

Networked: 34139 relevant articles (1303 outcomes, 4529 trials/studies) for this Drug, Comments

Relationship Network

Drug Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 52
  - Physiological Effects of Drugs: 1
    - Hormones, Hormone Substitutes, and Hormone Antagonists
      - Hormones: 52002
        Estrogens: 34139
        Non-Steroidal Estrogens: 7

Experts

1.	Sasano, Hironobu: 58 articles (01/2013 - 01/2003)
2.	Suzuki, Takashi: 47 articles (12/2012 - 01/2003)
3.	Hankinson, Susan E: 42 articles (10/2012 - 05/2002)
4.	Dowsett, Mitch: 38 articles (05/2012 - 01/2002)
5.	Miki, Yasuhiro: 32 articles (11/2012 - 06/2003)
6.	Jordan, V Craig: 32 articles (12/2011 - 01/2002)
7.	Hortobagyi, Gabriel N: 30 articles (01/2013 - 10/2002)
8.	Chlebowski, Rowan T: 30 articles (11/2012 - 01/2002)
9.	Zheng, Wei: 29 articles (11/2012 - 11/2002)
10.	Bernstein, Leslie: 27 articles (10/2012 - 01/2002)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 03/01/2000 - "The current study was conducted to investigate the efficacy of GAP31 and MAP30 on estrogen-independent and highly metastatic human breast tumor MDA-MB-231 both in vitro and in vivo. " 05/01/1992 - "The results of this study with human breast cancer cells suggest that 5a may be highly effective in the treatment of estrogen-dependent breast cancer and/or in the prophylactic treatment of women with a high risk of breast cancer development." 08/23/2012 - "Endocrine therapies that inhibit estrogen receptor (ER)-α signaling are the most common and effective treatment for ER-α-positive breast cancer. " 06/15/2012 - "Although endocrine therapy has dramatically improved the treatment of breast cancer therapeutic resistance and tumour recurrence occurs, even in estrogen receptor (ER) positive cases. " 12/01/2007 - "MDA-MB-231 is an estrogen receptor negative highly invasive human breast cancer cell line and has been used as a relevant model system to evaluate drugs with chemopreventive potential against highly invasive breast cancer phenotypes. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 01/01/1988 - "The features that most influenced prognosis within the categories defined by site of first relapse were disease-free interval (less than 24 months v greater than or equal to 24 months), and estrogen receptor content in the primary tumor. " 01/01/2004 - "In particular, we found a marked decrease in the number of apoptotic cells and debris after estrogen + irradiation, as compared to irradiation alone, only in younger patients and TNM 1+2 tumors. " 10/01/1994 - "One hundred sixty-seven good-risk patients with an estrogen receptor (ER+) positive recurrence or, in case of unknown receptor status, a disease-free interval (DFI) of greater than 12 months and < or = three recurrent tumor nodules each < or = 3 cm in diameter were entered onto the study. " 01/01/2007 - "The number of microvessels was significantly greater in the estrogen receptor-negative tumors (p < 0.001). " 01/01/2007 - "Our model significantly improved the survival prediction over other expression-based models and permitted recognition of patients with different prognoses within the estrogen receptor-positive group and within a single pathological tumor class. " Order ALL the reference details at left...
3.	Osteoporosis 09/01/2009 - "Currently, the nonhuman primate is the most widely used large animal model to evaluate the safety and efficacy of new drug entities to treat or prevent estrogen-deficiency-induced bone loss and osteoporosis. " 01/01/2008 - "Because of the striking resemblance of skeletal responses in humans and rats in the state of estrogen deficiency, the ovx rat is considered to be a gold standard model for evaluating drugs for prevention and reversal of osteoporosis. " 07/01/2009 - "Although estrogens, are not any more the first choice therapy for osteoporosis, the are still important and promising treatment option for women after menopause. " 09/01/2001 - "Estrogen, especially when begun early in menopause, has been shown to be beneficial in the prevention and treatment of osteoporosis. " 01/01/2000 - "Lower-dose combinations of continuous combined estrogen-progestin regimens are effective in increasing and maintaining BMD and provide a good endometrial safety profile for the long-term prevention of osteoporosis in postmenopausal women." Order ALL the reference details at left...
4.	Cardiovascular Diseases (Cardiovascular Disease) 10/01/2003 - "At the cellular level, estrogens have many effects on cardiovascular cells capable of being interpreted as beneficial in terms of cardiovascular disease. " 01/01/2010 - "Cardiovascular disease (CVD) is more common in postmenopausal than premenopausal women, suggesting vascular protective effects of estrogen. " 11/01/2008 - "Cardiovascular disease (CVD) is more prevalent in postmenopausal than premenopausal women, suggesting vascular protective effects of estrogen. " 11/01/2001 - "It is widely accepted that in women, estrogens provide protection against the development of cardiovascular disease. " 09/01/2007 - "Previous studies demonstrated the protective effects of estrogen administration in models of cardiovascular disease. " Order ALL the reference details at left...
5.	Carcinoma (Carcinomatosis) 09/02/2011 - "RPA extract includes chemical compounds with estrogen-like activity and validates its potential use as anticancer agent, particularly against breast carcinoma; provided important information potentially helpful in drug designing and discovery. " 02/15/1988 - "These characteristics are reflected in the marked efficacy with which it affects growth of estrogen-dependent 7,12-dimethylbenz(a)antracene-induced mammary carcinomas in intact female Sprague-Dawley rats. " 07/01/1975 - "In darkness the percentage of the take of the carcinoma proved to be less, and also the growth of the RMC-1 was delayed; there was also a marked increase in the efficacy of estrogen-therapy of mammary carcinoma. " 12/15/1980 - "This study corroborates previous reports which suggested the efficacy of estrogen receptor (ER) analysis in predicting responses of patients with metastatic mammary carcinoma to hormonal therapeutic manipulation. " 01/15/2011 - "Our findings highlight CXCR4 signaling as a rational therapeutic target for the treatment of ER-positive, estrogen-independent breast carcinomas needing improved clinical management." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tamoxifen
2.	Progesterone Receptors (Progesterone Receptor)
3.	Estrogens (Estrogen)
4.	Hormones
5.	Progesterone
6.	Aromatase Inhibitors
7.	Estrogen Receptor Modulators (Antiestrogen)
8.	Estradiol (Estrace)
9.	Progestins (Progestagens)
10.	Gonadotropin-Releasing Hormone (GnRH)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
3.	Estrogen Replacement Therapy
4.	Ovariectomy (Oophorectomy)
5.	Adjuvant Chemotherapy

blog comments powered by Disqus

TREATMENT OPTIONS
for Breast Neoplasms,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 5024 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>